Curing diabetes

The demand for insulin fluctuates with blood glucose levels, presenting a special challenge for would-be gene therapists. In the 23 November Nature, Lee et al. present their solution, which causes remission of autoimmune diabetes in mice for at least 8 months (Nature 2000, 408:483-488). A truncated insulin gene removes the need for proteolytic processing, a hepatocyte-specific, glucose-responsive promoter supplies the correct dosage, and an adeno-associated virus (AAV) delivers the necessary DNA

Written byWilliam Wells
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The demand for insulin fluctuates with blood glucose levels, presenting a special challenge for would-be gene therapists. In the 23 November Nature, Lee et al. present their solution, which causes remission of autoimmune diabetes in mice for at least 8 months (Nature 2000, 408:483-488). A truncated insulin gene removes the need for proteolytic processing, a hepatocyte-specific, glucose-responsive promoter supplies the correct dosage, and an adeno-associated virus (AAV) delivers the necessary DNA to liver cells. Glucose challenge elicited the correct response of increased insulin production, although this response was robust 2 hours after challenge and continued for almost 6 hours, as compared to the 30 minute response time and 1 hour duration seen in healthy animals. This delay probably arises because the gene therapy is controlled at the level of transcription, whereas insulin production is normally controlled at the level of secretion. The sustained response caused mild hypoglycemia in the treated ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies